Mercado de terapias antivirales: mapeo competitivo y perspectivas estratégicas para 2031

  • Report Code : TIPRE00012650
  • Category : Life Sciences
  • No. of Pages : 170
Buy Now

Se espera que el mercado mundial de terapias antivirales crezca de 47.228,91 millones de dólares en 2021 a 82.928,76 millones de dólares en 2031; se estima que crecerá a una tasa compuesta anual del 8,4 % entre 2022 y 2031.

 

Las terapias antivirales implican el desarrollo de un tratamiento para infecciones virales. Se utilizan varias estrategias para desarrollar una terapia antiviral, incluidos los antivirales de acción directa que se dirigen a proteínas, enzimas o ácidos nucleicos virales; anticuerpos pasivos que neutralizan los virus circulantes; y medicamentos que se dirigen a proteínas celulares o procesos esenciales para la replicación viral.

 

El mercado de terapias antivirales se atribuye al aumento del gasto en I+D de las empresas farmacéuticas y al creciente apoyo gubernamental a las actividades de investigación. y ensayos clínicos. Sin embargo, el alto coste del desarrollo de fármacos está obstaculizando el crecimiento del mercado.

 

El mercado de terapias antivirales está segmentado según el tipo y la aplicación. , mecanismo de acción y geografía. El informe ofrece información y un análisis en profundidad del mercado de terapias antivirales, enfatizando varios parámetros como las tendencias del mercado, los avances tecnológicos y la dinámica del mercado, así como el análisis del panorama competitivo de los principales actores del mercado.

 

regiones lucrativas del mercado de terapias antivirales

Anti-Viral Therapies Market< /p>

Perspectivas del mercado

El aumento del gasto en I+D de las empresas farmacéuticas impulsa el crecimiento del mercado de terapias antivirales

 

La investigación y el desarrollo (I+D) son una parte esencial del negocio de una empresa. Las empresas farmacéuticas se centran en la I+D para introducir nuevos medicamentos con mayor potencial médico y comercial. Estas empresas invierten principalmente en Actividades de I+D con el objetivo de ofrecer productos innovadores y de alta calidad en el mercado.

Inversiones en I+D de las principales empresas farmacéuticas

Anti-Viral Therapies Market

 

Nota: se considera la tasa de conversión actual.

Fuente: Informes anuales y análisis de Insight Partners

El gasto en I+D de las empresas biofarmacéuticas ha aumentado a lo largo de los años. Según el informe de Pharmaceutical Research and Manufacturers of America (PhRMA), el gasto en I+D de las empresas biofarmacéuticas aumentó de dólares estadounidenses 49.600 millones en 2012 a 58.800 millones de dólares en 2015. En el año fiscal 2014-2015, 16 empresas farmacéuticas se encontraban entre las 50 principales empresas del mundo en términos de inversión total en I+D. Novartis, Roche, Johnson & Johnson, y Pfizer se encuentran entre las 10 principales empresas inversoras en I+D a nivel mundial. Además, en 2021, Astellas Pharma invirtió 1.803,70 millones de dólares en I+D de medicamentos nuevos y avanzados. Por lo tanto, se prevé un aumento del gasto en I+D impulsar el mercado de terapias antivirales durante el período de pronóstico.

 

Información basada en tipografía

Según el tipo, el mercado de terapias antivirales se divide en medicamentos genéricos y medicamentos de marca. El segmento de medicamentos de marca tuvo una mayor participación del mercado en 2021; sin embargo, se prevé que el segmento de medicamentos genéricos aumente registre una CAGR más alta durante el período de pronóstico.

                                              &n bsp;                

Mercado de terapias antivirales, por tipo: 2021 y 2031

Anti-Viral Therapies Market

Mecanismo de insights basados en acciones

Según el mecanismo de acción, el mercado de terapias antivirales se segmenta en inhibidores de la nucleótido polimerasa, inhibidores de la transcriptasa inversa, inhibidores de la proteasa y otros. El segmento de inhibidores de la nucleótido polimerasa tenía la mayor participación del mercado en 2021; Además, se prevé que el segmento de inhibidores de la transcriptasa inversa registre la CAGR más alta del mercado durante el período de pronóstico debido a su eficacia para reducir la propagación de infecciones virales. Por lo tanto, se espera que la necesidad y el uso de inhibidores de la transcriptasa inversa aumenten en en los próximos años, lo que probablemente impulsará el crecimiento del mercado en todo el mundo.

 

Información basada en aplicaciones

Según la aplicación, el mercado mundial de terapias antivirales se segmenta en VIH, hepatitis, herpes, virus de la influenza y otras aplicaciones. El segmento del VIH tuvo la mayor participación del mercado en 2021. Además, Se estima que el segmento de hepatitis registrará la CAGR más alta durante el período de pronóstico.

 

Por geografía, el mercado global está segmentado en América del Norte (EE.UU., Canadá y México), Europa (Reino Unido, Alemania, Francia, Italia, España y resto de Europa), Asia Pacífico (China , Japón, India, Australia, Corea del Sur y resto de Asia Pacífico), Medio Oriente y África (Emiratos Árabes Unidos, Arabia Saudita, África y resto de Medio Oriente y África) y América del Sur y Central (Brasil, Argentina y resto de América del Sur y Central).

 

Se espera que el mercado de terapias antivirales de Asia Pacífico crezca al ritmo más rápido durante el período de pronóstico. Se estima que el mercado crecerá durante el período de pronóstico debido a la creciente industria farmacéutica en China, Japón, India y otros países de Asia Pacífico. Es probable que la creciente incidencia de enfermedades virales en la región y el creciente desarrollo de productos por parte de los actores del mercado local e internacional favorezcan el crecimiento del mercado. Además, la industria farmacéutica de China se encuentra entre las industrias farmacéuticas más grandes del mundo. mundo. El país ha mostrado un crecimiento significativo en ingrediente farmacéutico activo fabricación, competitividad, innovaciones y formación de dosis finales. De ahí que la mayoría de las empresas multinacionales estén mostrando interés en el mercado chino para la venta de medicamentos.

 

Es probable que los crecientes esfuerzos de los gobiernos de varios países y las empresas farmacéuticas y de biotecnología para tratar a los pacientes con COVID-19 impulsen el crecimiento del mercado de terapias antivirales durante el período de pronóstico. En los EE. UU., la FDA ha aprobado la autorización de uso de emergencia de medicamentos experimentales. Ensayos clínicos de remdesivir, monoclonal Se han registrado anticuerpos, interferones, inhibidores de la ECA e hidroxicloroquina en los EE. UU. Además, las empresas farmacéuticas del país están haciendo enormes esfuerzos para desarrollar medicamentos y vacunas para el tratamiento de pacientes con COVID-19. Los científicos de la Universidad de Oxford habían estado probando medicamentos existentes como terapias para pacientes con COVID-19. Además, en julio la Comisión Europea autorizó remdesivir, lo que lo convierte en el primer fármaco aprobado para el tratamiento de la COVID-19 en la Unión Europea.

 

Perfiles de empresa

Algunos de los principales actores que operan en el mercado de terapias antivirales incluyen AbbVie Inc.; Abad; F. Hoffmann-La Roche Ltd; Compañía Bristol-Myers Squibb; Johnson & Servicios Johnson, Inc.; Merck & Co., Inc.; Ciencias de Gilead, Inc.; GlaxoSmithKline plc; y Aurobindo Pharma Limited.

  • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
  • PEST and SWOT Analysis
  • Market Size Value / Volume - Global, Regional, Country
  • Industry and Competitive Landscape
  • Excel Dataset
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Who are the major players in the anti-viral therapies market?

The anti-viral therapies market majorly consists of the players such as AbbVie Inc., Abbott, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Merck & Co., Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, AstraZeneca and Aurobindo Pharma Limited amongst others.

What are the driving factors for the anti-viral therapies market across the globe?

The factors that are driving growth of the market are growing prevalence of viral diseases, increasing R&D expenditures in pharmaceutical companies and rising government support for research activities and clinical trials. Moreover, emerging markets is expected to offer lucrative opportunities for the growth of the market.

What is anti-viral therapies?

Antiviral therapies is one of the most exciting branches of virology, which involves developing a treatment for viral infections. There are several strategies used to develop antiviral therapy, including direct-acting antivirals that target viral proteins, enzymes, or nucleic acids; passive antibodies that neutralize circulating viruses; drugs that target cellular proteins or processes essential for viral replication.

Trends and growth analysis reports related to Life Sciences : READ MORE..   
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

The List of Companies - Anti- Viral Therapies Market

  1. AbbVie Inc.
  2. Abbott
  3. F. Hoffmann-La Roche Ltd
  4. Bristol-Myers Squibb Company
  5. Johnson & Johnson Services, Inc.
  6. Merck and Co., Inc.
  7. Gilead Sciences, Inc.
  8. GlaxoSmithKline plc
  9. Aurobindo Pharma
  10. AstraZeneca

Buy Now  

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.